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ABSTRACT
Purpose: Although mild to moderate asthma is much more common, the morbidity and 
mortality of severe asthma are much higher. This study was performed to identify and analyze 
the clinical characteristics of severe asthma in Korea.
Methods: We registered patients with severe refractory asthma into the Severe Asthma 
Registry supported by the Severe Asthma Work Group of the Korean Academy of Asthma, 
Allergy and Clinical Immunology. Patients were enrolled since 2010 from the 15 university 
hospitals nationwide in Korea. Severe asthma was defined according to modified European 
Respiratory Society/American Thoracic Society criteria. Information on demographics, 
medical history, pulmonary function tests and skin prick tests was collected; the clinical 
characteristics of severe asthmatics were analyzed from the collected data.
Results: A total of 489 patients were enrolled with a mean age of 62.3; 45% are male. Sixty 
percent of patients received Global Initiative for Asthma step 4 treatment, and 30% received 
step 5 treatment. The most common comorbidities were allergic rhinitis (58.7%). Aspirin 
hypersensitivity was observed in 14.0%. Approximately half (53.9%) are non-smokers. Atopy 
was proven in 38.5% of the patients. Regarding asthma medications, inhaled corticosteroids 
and long-acting β-agonist combination inhalers were most commonly prescribed (96.5%), 
followed by leukotriene antagonists (71.0%). A recombinant anti-immunoglobulin E 
monoclonal antibody (omalizumab) has been used in 1.8% of the patients. The mean forced 
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vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and FEV1/FVC were 78.7%, 
67.5% and 67.9% of predicted values, respectively. The mean Asthma Control Test and quality 
of life questionnaire scores were 16.5 out of 25 and 59.5 out of 85, respectively.
Conclusions: The baseline characteristics of severe asthma patients in the Korea Severe 
Asthma Registry were analyzed and reported for the first time. With this cohort, further 
prospective studies should be performed to search for ways to improve management of severe 
refractory asthma.
Keywords: Asthma; severe asthma; registry
INTRODUCTION
Asthma, characterized by chronic airway inflammation and airway hyperreactivity, varies 
from mild to severe depending on clinical signs and symptoms.1 Asthma is one of the most 
prevalent diseases, accounting for more than 30% of respiratory diseases according to the 
Asia-Pacific Burden of Respiratory Diseases (APBORD) surveillance study.2 Severe asthma 
refers to asthma that requires treatment with high-dose inhaled corticosteroids (ICS) to 
maintain control or that remains uncontrolled despite this treatment.3 The prevalence of 
severe asthma has been reported to be about 5%–10%,4-7 yet it is difficult to determine its 
exact prevalence. The reason for this is that the definition of severe asthma has not been 
clearly established and that the term ‘severe asthma’ has been used to indicate both difficult-
to-control asthma and severe refractory asthma.7-9 However, since the Paris Workshop in 
2007, severe refractory asthma began to be distinguished from difficult-to-treat asthma.10,11 
Difficult-to-treat asthma describes cases that remain uncontrolled due to correctable factors 
such as environmental exposures, comorbidities, poor compliance, inadequate inhaler 
technique and other reasons.
Nevertheless, severe asthma is still defined differently by different study groups. For 
this reason, clinical characteristics of severe asthma have not been clearly identified. 
Furthermore, subgroups with various clinical features are observed among study subjects 
with severe asthma, and depending on the heterogeneous phenotypes, future biologic 
treatment is also expected to vary.3,7,11 Severe asthma accounts for only a small portion of 
the total asthma population, but it causes a large portion of asthma morbidity and medical 
resource expenditure.12 Therefore, it is important to understand the current epidemics and 
characteristics of severe asthma. Across the Asia-Pacific region, the economic burden of 
asthma, chronic obstructive pulmonary disorder (COPD) and rhinosinusitis was examined, 
and the annual cost per patient with respiratory disease was US $8,853.2 Among them, severe 
asthma, which accounts for only 10%-20% of total asthma patients, accounts for more 
than 50% of the total cost of asthma.13 Hence, it is important to determine the economic 
burden of severe asthma and to use and distribute healthcare resources. Although many 
studies of severe asthma in Korea have currently been conducted,14-16 the status of severe 
asthma in the community is not precisely characterized. There are many cohort studies in 
the western countries with severe asthmatics, but there is no assurance that these study 
results will represent severe asthma patients in Asia.17,18 In this study, we report the overall 
clinical features of Korean severe asthma patients by analyzing data from Severe Asthma 
Registry, the official severe asthma network, consisting of 15 university hospitals nationwide, 
supported by the Severe Asthma Work Group of the Korean Academy of Asthma, Allergy and 
Clinical Immunology (KAAACI). In addition, asthma severity tends to increase as Global 
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Initiative for Asthma (GINA) treatment step goes up.19 In order to determine which features 
are more prominent as the severity of asthma increases, we intended to compare the clinical 
differences according to the GINA treatment steps.
MATERIALS AND METHODS
Study design
Starting in 2010, we prospectively enrolled patients with severe asthma from the 15 university 
hospitals nationwide in Korea. Severe asthma was defined as follows: patients who do not 
consistently reach a well-controlled state even after GINA treatment step 4 or 520; patients 
who have reached a well-controlled state but have more than 1 urgent care visit a year, need 
steroid burst treatment more than 3 times a year or experience exacerbation when oral or 
ICS are reduced 25%; or patients who have had a near-fatal asthma attack anytime in the 
past. Demographic information including sex, age, comorbidities, past medical history, 
pet ownership, smoking history, family history of allergic disease, unscheduled healthcare 
visits or corticosteroid burst treatment, and asthma-related questionnaires (Asthma Control 
Test [ACT],21 quality of life questionnaire in adult Korean asthmatics [QLQAKA]22) were 
collected from patient questionnaires. Body mass index (BMI), laboratory tests, pulmonary 
function tests, allergen skin prick test and medication prescription data were provided by 
physicians. From these data, the characteristics of severe asthma were analyzed. To determine 
whether there is any difference in clinical features according to disease severity, we compared 
characteristics of patients receiving GINA treatment step 4 with those of patients receiving step 
5 treatment. The study was approved by the Institutional Review Board of the ethics committee 
of each hospital (Ewha Womans University Mokdong Hospital IRB number: 2013-01-001).
Statistical analysis
All data with normal distribution are expressed as mean ± standard deviation or number 
(%). Data with non-normal distribution were analyzed by median values. Student's t test or 
the Mann-Whitney U test was used for continuous variables and chi-square test or Fisher's 
exact test was used for categorical variables. A P value<0.05 was considered significant. All 
statistical analyses were done using SPSS version 20.0 (IBM Corp., Armonk, NY, USA).
RESULTS
In total, 489 severe asthmatic patients were enrolled. Mean age was 62.3 ± 14.0 years and 
45.1% are male. The mean age at the diagnosis of asthma was 45 years, with an average of 10 
years of asthma treatment (Table 1). Comorbid diseases were frequent in the following order: 
allergic rhinitis, hypertension and gastroesophageal reflux disease (Table 2). Current and ex-
smokers accounted for 46% of the patients. Aspirin-exacerbated respiratory disease (AERD) 
was reported on the questionnaire by 14% of the the patients. Fourteen percent were pet 
owners, and 47% of the patients reported having a family history of allergic diseases, such as 
asthma, allergic rhinitis, and atopic dermatitis. Atopy was found in approximately one third 
of the patients. Most of the atopic patients were sensitized to house dust mites, followed by 
pollen, animals and mold. A history of atopic dermatitis, allergic conjunctivitis and atopy 
seemed to be more common in the patients receiving GINA treatment step 4, and anxiety 
disorder seemed to be more prevalent in those receiving GINA treatment step 5, although 
the differences were not statistically significant. However, a family history of allergic disease 
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and pollen sensitization were significantly more common in the GINA step 4 group, while 
hypertension was more common in the GINA step 5 group. Other characteristics were not 
different between the 2 groups (Table 1).
Mean forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and FEV1/FVC 
values were 78.7%, 67.5% and 67.9%, respectively. Mean peripheral blood eosinophil count was 
429.1/µL, and the proportion of patients with blood eosinophils greater than 300/µL was 41.4%. 
Sputum eosinophil counts were available in 196 patients; their mean sputum eosinophil count 
was 17.5%. Among them, 105 (53.3%) had sputum eosinophil counts more than 3%. Mean 
total immunoglobulin E (IgE) and fractional exhaled nitric oxide (FeNO) were 466.0 IU/mL 
and 41.1 ppb, respectively (Table 3). Mean FVC (%, mL) and FEV1 (%, mL) were significantly 
lower in the patients receiving GINA treatment step 5 than in those receiving step 4 treatment 
(GINA treatment step 4 vs. 5: 80.2% ± 17.4% vs. 74.9% ± 16.4%, P = 0.002; 2,661.9 ± 821.7 mL 
vs. 2,397.8 ± 809.9 mL, P = 0.002; 68.8% ± 17.3% vs. 64.0% ± 20.5%, P = 0.019; 1,795.9 ± 642.9 
mL vs. 1,656.6 ± 757.2 mL, P = 0.047, respectively). Proportions of sputum neutrophils and 
lymphocytes were higher in patients receiving GINA step 4 treatment (60.0% ± 32.1% [step 4] 
vs. 48.9% ± 33.9% [step 5], P = 0.028; 3.4% ± 9.8% [step 4] vs. 1.0% ± 1.8% [step 5], P = 0.012) 
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Table 1. Comparison of baseline characteristics according to GINA guideline treatment step
Characteristics Severe asthma (n = 489) GINA step 4 (n = 293) GINA step 5 (n = 153) P value
Age (yr) 62.3 ± 14.0 62.7 ± 14.0 62.3 ± 14.1 0.737
Sex (male) 220 (45.1) 129 (44.2) 74 (48.4) 0.424
BMI (kg/m2) 24.0 ± 3.8 24.0 ± 3.9 23.9 ± 3.5 0.618
Onset of asthmatic symptoms (yr) 40.8 ± 17.4 40.6 ± 18.0 42.0 ± 15.1 0.382
Asthma diagnosis (yr) 44.8 ± 16.3 45.2 ± 16.9 44.4 ± 14.8 0.592
Asthma treatment (yr) 46.5 ± 15.8 47.1 ± 16.5 45.3 ± 14.6 0.278
Duration of asthma treatment 10.5 ± 9.8 10.6 ± 11.1 10.9 ± 8.2 0.824
Aspirin hypersensitivity (AERD) 62/444 (14.0) 40 (15.3) 21 (14.5) 0.885
Pet owners 69 (14.1) 43 (15.0) 18 (11.8) 0.388
Smoking history - 12.1 ± 26.7 13.1 ± 24.0 0.679
Never smoker 262 (53.9) 156 (53.6) 84 (54.9) 0.255
Ex-smoker 164 (33.7) 95 (32.6) 56 (36.6) -
Current smoker 60 (12.3) 40 (13.7) 13 (8.5) -
Family history of allergic disease 224/472 (47.5) 143 (50.9) 58 (38.4) 0.015
Atopy 104/270 (38.5) 68 (40.7) 20 (27.8) 0.059
Sensitization to house dust mite 91 (33.7) 59 (20.1) 25 (16.3) 0.373
Sensitization to pollen 44 (16.3) 36 (12.3) 9 (5.9) 0.046
Sensitization to animal 37 (13.7) 25 (8.5) 10 (6.5) 0.674
Sensitization to mold 9 (3.3) 8 (2.7) 2 (1.3) 0.505
Data are presented as mean ± standard deviation or number (%).
GINA, Global Initiative for Asthma; BMI, body mass index; AERD, aspirin exacerbated respiratory disease.
Table 2. Comorbidities and past medical histories according to GINA guideline treatment step
Comorbidities/past medical histories Severe asthma (n = 489) GINA step 4 (n = 293) GINA step 5 (n = 153) P value
Allergic rhinitis 267/455 (58.7) 164 (60.3) 82 (55.8) 0.406
Atopic dermatitis 42/480 (8.8) 32 (11.2) 8 (5.2) 0.054
Allergic conjunctivitis 31/482 (6.4) 23 (8.0) 5 (3.3) 0.064
GERD 61/480 (12.7) 36 (12.6) 15 (9.9) 0.438
Sleep apnea 8/479 (1.7) 4 (1.4) 5 (2.6) 0.458
Anxiety disorder 8/479 (1.7) 2 (0.7) 5 (3.3) 0.054
Depressive disorder 19/482 (3.9) 12 (4.2) 6 (3.9) 1.000
Hypertension 148/481 (30.8) 79 (27.5) 59 (38.6) 0.018
Heart failure 8/478 (1.7) 3 (1.1) 5 (3.3) 0.134
Pulmonary tuberculosis 22/475 (4.6) 14 (4.9) 6 (3.9) 0.647
Pneumonia 43/475 (9.1) 25 (8.8) 14 (9.3) 1.000
Data are presented as number (%).
GINA, Global Initiative for Asthma; GERD, gastroesophageal reflux disease.
and sputum macrophages were higher in patients receiving GINA step 5 treatment (16.6% 
± 22.4% [step 4] vs. 30.7% ± 30.9% [step 5], P = 0.001). There was no significant difference 
between the GINA step 4 and 5 treatment groups for the other laboratory tests (Table 3).
Ninety-eight percent of the patients were using ICS as a treatment for asthma, and 95% were 
using ICS + long-acting beta-2 agonists (LABA). Three severe asthmatic patients reported 
that they did not continuously use ICS after they got treated with continuous or intermittent 
systemic corticosteroids. Among patients using ICS, fluticasone was the most commonly 
used ICS type, followed by budesonide. The most commonly used oral asthma controllers 
were leukotriene receptor antagonist (LTRA) and methylxanthine (Fig. 1). Short-acting 
beta-2 agonists were also used frequently (37.6%). When comparing the asthma medications 
according to the GINA treatment step, the use of ICS + LABA was higher in patients receiving 
GINA treatment step 4 than in those receiving step 5 treatment (99.3% vs. 92.8%, P < 0.001). 
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Table 3. Comparison of pulmonary function and laboratory test values according to GINA guideline treatment step
Pulmonary function/laboratory test Severe asthma (n = 465) GINA step 4 (n = 278) GINA step 5 (n = 146) P value
Mean FVC (%) 78.7 ± 17.0 80.2 ± 17.4 74.9 ± 16.4 0.002
Mean FVC (mL) 2,590.8 ± 842.6 2,661.9 ± 821.7 2,397.8 ± 809.9 0.002
Mean FEV1 (%) 67.5 ± 18.5 68.8 ± 17.3 64.0 ± 20.5 0.019
Mean FEV1 (mL) 1,761.0 ± 688.1 1,795.9 ± 642.9 1,656.6 ± 757.2 0.047
Mean FEV1/FVC (%) 67.9 ± 13.1 67.9 ± 12.7 68.0 ± 14.5 0.975
WBC (/µL, n = 437) 8,820.3 ± 5,250.0 8,540.7 ± 4,874.1 8,928.1 ± 2,864.0 0.381
Blood eosinophil (%, n = 434) 5.0 ± 5.7 5.3 ± 6.4 4.3 ± 4.4 0.075
Blood eosinophil (/µL, n = 433) 429.1 ± 859.8 464.4 ± 1,075.2 353.3 ± 387.1 0.231
Blood eosinophil ≥ 300 (/µL) 178/430 (41.4) 103 (41.2) 58 (40.0) 0.832
Total IgE (IU/mL, n = 250) 466.0 ± 736.0 452.0 ± 707.4 525.9 ± 844.6 0.492
Sputum cell counts (n = 197)
Macrophages 21.6 ± 26.8 16.6 ± 22.4 30.7 ± 30.9 0.001
Neutrophils 55.4 ± 33.0 60.0 ± 32.1 48.9 ± 33.9 0.028
Lymphocytes 2.5 ± 7.6 3.4 ± 9.8 1.0 ± 1.8 0.012
Eosinophils 17.5 ± 26.1 17.0 ± 26.7 16.5 ± 23.5 0.899
Sputum eosinophil > 3% 105 (53.3) 55 (48.7) 40 (58.8) 0.220
FeNO (ppb) (n = 30) 41.1 ± 26.4 39.0 ± 25.2 53.7 ± 30.9 0.239
Data are presented as mean ± standard deviation or number (%).
GINA, Global Initiative for Asthma; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; WBC, white blood cells; IgE, immunoglobulin E; FeNO, 





















































Fig. 1. The composition of ICS types (A). The percentage of use of other controllers or rescue medication (B). 
ICS, inhaled corticosteroids; LTRA, leukotriene receptor antagonist; IgE, immunoglobulin E; Ab, antibody.
This is probably due to the fact that more patients in the GINA step 5 treatment group were 
maintained on systemic corticosteroids (0.0% vs. 60.1%, P < 0.001). Omalizumab (anti-IgE 
antibody) tended to be used more frequently in patients receiving GINA treatment step 5 than 
in those receiving GINA treatment step 4 (0.7% vs. 4.6%, P = 0.010). Although there was no 
difference in total ICS dose, total systemic corticosteroid dose was significantly higher in 
patients receiving GINA treatment step 5 than in those receiving step 4 treatment (541.4 ± 
963.9 mg vs. 1,442.4 ± 1,599.9 mg, P < 0.001) (Table 4).
The proportion of patients who unexpectedly visited a healthcare facility during the previous 
year (including unscheduled outpatient clinic visit, emergency room visit or hospitalization) 
was approximately 15%. Few patients (0.6%) were ever admitted to an intensive care unit (ICU) 
(Fig. 2A). The number of unscheduled outpatient clinic visits was larger in patients receiving 
step 5 treatment than in those receiving step 4 treatment (1.92 ± 1.59 vs. 3.25 ± 2.65, P = 0.029). 
Other unexpected visits and number of unscheduled visits were not different according to the 
GINA treatment step (Table 5). Forty-one percent of patients received at least one steroid burst 
treatment per year, and 24.3% of patients required more than three steroid burst treatments 
per year (Fig. 2B). The frequency of systemic corticosteroid burst treatment was also higher in 
the GINA treatment step 5 group (2.00 ± 1.51 [step 4] vs. 3.10 ± 1.98 [step 5], P < 0.001).
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Table 4. Comparison of prescribed asthma medications according to GINA guideline treatment step
Asthma medications Severe asthma (n = 489) GINA step 4 (n = 293) GINA step 5 (n = 153) P value
Drugs
ICS+LABA 472 (96.5) 291 (99.3) 142 (92.8) < 0.001
ICS+LABA+LTRA 337 (68.9) 204 (69.6) 104 (68.0) 0.747
ICS+LABA+LAMA 143 (29.2) 89 (30.4) 42 (27.5) 0.584
LTRA 347 (71.0) 205 (71.4) 112 (74.2) 0.575
Methylxanthines 279 (57.1) 167 (58.6) 92 (61.7) 0.538
Anticholinergics 150 (30.7) 89 (31.8) 49 (32.9) 0.829
Sustained systemic corticosteroids 92 (18.8) 0 (0.0) 92 (60.1) < 0.001
Anti-IgE antibody 9 (1.8) 2 (0.7) 7 (4.6) 0.010
ICS dose in the previous year (mcg/day, budesonide) 1,102.0 ± 732.7 1,101.3 ± 691.4 1,170.1 ± 776.2 0.340
Total systemic corticostseroids dose in the previous 
year (mg, prednisolone)
802.7 ± 1,252.1 541.4 ± 963.9 1,442.4 ± 1,599.9 < 0.001
Data are presented as mean ± standard deviation or number (%).
GINA, Global Initiative for Asthma; ICS, inhaled corticosteroids; LABA, long-acting beta-2 agonists; LTRA, leukotriene receptor antagonist; IgE, immunoglobulin E.
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Fig. 2. The percentage of patients who visited a healthcare facility unexpectedly (A) and the percentage of patients who were prescribed systemic 
corticosteroids burst treatment (B). 
ER, emergency room; ICU, intensive care unit.
The mean ACT score was 16.5 out of 25 and the mean QLQAKA score was 59.5 out of 85. ACT 
and QLQAKA scores were not different between the 2 treatment groups (Table 5).
DISCUSSION
In this study we evaluated the current status of severe asthma patients being treated at 
tertiary university hospitals in Korea and it is the first cohort analysis in real world targeted 
only severe asthmatic patients in Korea. We found that some clinical features of severe 
asthma in Korean patients were unique compared to those of patients in other countries, and 
the burden of severe asthma was substantial. In addition, our study has shown that there is a 
difference in clinical features among patients with severe asthma according to their severity. 
Compared to the GINA step 4 treatment group, the GINA step 5 treatment group showed 
lower lung function, lower allergic tendency and higher neutrophilic airway inflammation. 
These results suggest that the higher severity in asthma patients, the more likely have an 
inflammation similar to COPD, rather than an allergic inflammation. We also confirmed 
that severe asthma is an area of unmet need in asthma, and it is anticipated that further 
studies based on this cohort will be possible to search for better management strategies for 
asthma in Korea. The prevalence of severe or difficult-to-treat asthma has been reported 
to be approximately 5%–10%.4-6 In a study conducted in the Netherlands, severe refractory 
asthma accounted for 3.6% of all asthma patients.8 Because we recruited only patients with 
severe asthma in this study, it is impossible to estimate the prevalence of severe asthma or 
proportion of patients with severe asthma among all patients with asthma. However, we have 
enrolled almost 500 patients from 15 hospitals nationwide so far; thus, the clinical features of 
severe asthma in Korea can be identified with this severe asthma registry data.
The results of this study showed that severe asthmatic patients in Korea were relatively old 
with treatment duration of approximately 10 years, and that half of them had a smoking 
history. Unlike our study, in the National Heart Lung and Blood Institute-sponsored Severe 
Asthma Research Program (SARP), the age of the subjects was much younger (37 years).17 
In the European Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes 
(U-BIOPRED), the mean age of recruited severe asthmatic patients was in their 50s.18 
Interestingly, the duration of asthma was more than 20 years in both SARP and U-BIOPRED 
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Table 5. Comparison of unexpected healthcare visits according to GINA guideline treatment step
Unexpected healthcare use Severe asthma (n = 489) GINA step 4 (n = 293) GINA step 5 (n = 153) P value
Presence of unscheduled visit in the previous year
Outpatient 75 (15.3) 47 (16.4) 17 (11.3) 0.158
ER 65 (13.3) 33 (11.5) 27 (17.9) 0.079
Hospitalization 89 (18.2) 53 (18.5) 30 (19.9) 0.798
ICU admission 3 (0.6) 1 (0.4) 2 (1.3) 0.272
Number of unscheduled visits in the previous year
Outpatient 2.37 ± 2.16 1.92 ± 1.59 3.25 ± 2.65 0.029
ER 0.24 ± 1.44 0.16 ± 0.47 0.23 ± 0.56 0.133
Hospitalization 0.28 ± 0.81 0.27 ± 0.76 0.33 ± 0.95 0.473
ICU admission 0.006 ± 0.079 0.004 ± 0.059 0.013 ± 0.115 0.327
Systemic corticosteroid burst treatment 2.34 ± 1.74 2.00 ± 1.51 3.10 ± 1.98 < 0.001
ACT (n = 463) 16.5 ± 5.9 16.2 ± 6.0 16.7 ± 5.8 0.397
QLQAKA (n = 437) 59.5 ± 16.7 60.0 ± 17.1 58.6 ± 15.8 0.417
Data are presented as mean ± standard deviation or number (%).
GINA, Global Initiative for Asthma; ER, emergency room; ICU, intensive care unit; ACT, asthma control test; QLQAKA, quality of life questionnaire in adult Korean 
asthmatics.
studies, which was much longer than that in our study. It is unclear why the average age and 
treatment duration of severe asthma differ among Korea and other countries, but it may be 
due to differences in the basic epidemiology, especially the proportion of smokers. While the 
proportion of smokers was approximately 50% in our study, SARP was targeted to non-smoking 
(less than 5 pack-years of smoking history) asthmatic patients,17 and 110 out of 421 (26.1%) 
severe asthmatic patients in the U-BIOPRED were smokers or ex-smokers.18 The percentage of 
smokers in the study population or the difference in ethnic background in different countries 
may have affected the results of the studies. In addition, the inclusion of patients with asthma-
COPD overlap (ACO) could have contributed to the differences among the studies.
In this study, AERD was observed in 14%. In contrast, AERD accounted for 8% in the Belgian 
Severe Asthma Registry,23 indicating that AERD is found slightly more often in Korean 
patients with severe asthma. A family history of allergic diseases such as asthma, allergic 
rhinitis or atopic dermatitis was observed in approximately half of the patients in our study. 
However, that information cannot be compared because it was not provided in the SARP 
and U-BIOPRED studies. In addition, in our study the percentage of patients with atopy was 
approximately one third, whereas it was over 70% in the SARP and U-BIOPRED studies.17,18 
This may also reflect an ethnic difference, but because our registry contains more smokers 
and elderly people than other cohorts, it is possible that there could be many patients with 
ACO features rather than allergic asthmatics.
With regard to pulmonary function, both the predicted FEV1 value and FEV1/FVC ratio 
were less than 70% in this study, which is similar to features of COPD. However, the results 
of induced sputum analysis showed that the proportion of patients with > 3% sputum 
eosinophil count was 53% and that total IgE, FeNO and atopic rate were also high, showing 
the characteristics of asthma at the same time. These results mean that severe asthmatic 
patients in our study have features of ACO. In the SARP data, FEV1 was 74% and the FEV1/
FVC ratio was 0.7, which was slightly higher than in our study.17 This is probably due to the 
fact that our study population is older and has more smokers. In the U-BIOPRED study, FEV1 
was 67% and the FEV1/FVC ratio was 0.61–0.64, which are similar to the results of our study.18
Interestingly, in the SARP study, blood eosinophil, sputum eosinophil, and FeNO were 
0.2%–0.3%, 0.7%–1.9% and 24.8–32.8 ppb, respectively.17 In addition, in the U-BIOPRED 
study, blood eosinophil, sputum eosinophil and FeNO were 2.9%, 2.8%–4.1% and 23.5–26.5 
ppb, respectively; both sets of results are much lower than in our study (5%, 17.5% and 41.1 
ppb).18 This is probably caused by differences in race, environment, age or measurement 
method, but the FeNO level is high in patients with elevated eosinophil counts; therefore, 
patients enrolled in our study may have increased eosinophilic inflammation.24 The reason 
for this difference is still unclear and needs further research.
Although almost all the patients in this study were treated with ICS + LABA, 13% of the 
patients visited the emergency room, 18% and 0.6% of the patients were admitted to general 
wards and the ICU, respectively, and 41% of the patients were treated with steroid burst 
therapy because of asthma exacerbation within 1 year. In the SARP study, 78% of the patients 
were using ICS + LABA. The rate of exacerbation was found to be higher in SARP than in our 
study. In the SARP study, 30% of the patients visited ER, and 14% and 7% of the patients were 
admitted to general wards and ICU within 1 year, respectively; however, 28% of patients in 
the SARP study were treated with steroid burst more than 3 times a year, which is comparable 
to 24.3% in our study (data not shown).17 The lower rate of ER visits and ICU admission in 
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our study is likely to be related to the higher use of ICS+LABA than in the SARP group. It is 
also possible that our country has a good accessibility to hospitals or clinics; therefore, there 
is lower risk of severe exacerbations and patients may be managed earlier even if asthma 
exacerbation occurs. In the U-BIOPRED study, ICS and LABA were used in over 98% of severe 
asthmatics; however, there was no other data about unexpected healthcare use and the 
number of exacerbations in 1 year was 2.48–2.55.18 In another European population-based 
study, asthmatic patients using daily ICS were 17%–24%, which is much lower compared 
to this study, while asthma attack in the past year was 36%–43% and exacerbation rate was 
10%–15%, similar to the results of this study.25
Severe asthmatic patients were not well controlled according to ACT and QLQAKA scores.21,26 
SARP did not present data on asthma control and U-BIOPRED used the Asthma Control 
Questionnaire and the Asthma Quality of Life Questionnaire which are different indices 
than our study. Thus, direct comparison of asthma control status among the studies was 
impossible.17,18 However, severe asthmatics in U-BIOPRED also had poorly controlled asthma 
and poor quality of life, similar to subjects in our study.
In this study, omalizumab is used in only 1.8% of the severe asthma patients, which is much 
less compared to other countries such as the US and many European countries. Recent 
studies have reported that short-term and long-term therapy with omalizumab showed 
reduction in symptoms, exacerbations, and medications and improvement in lung functions 
without any safety concerns.27,28 Given the frequent use of systemic corticosteroids for the 
patients in this study, omalizumab could be more frequently considered as an alternate 
therapeutic option. However, we have to consider that it is not reimbursed by the Korean 
insurance system. In addition, it is possible that in this Korean severe asthma registry, the 
proportion of severe asthmatic patients with IgE-mediated allergic asthma is relatively low, 
probably due to ethnic difference, although the precise cause should be further studied.
Meanwhile, a large number of severe asthmatic patients has severe eosinophilic asthma, 
which can be a candidate asthma subtype for other biologics such as anti-interleukin (IL)-5 
therapy.29 Various biologics including several anti-IL-5 biologics such as mepolizumab, 
reslizumab, and benralizumab are newly-marketed or are expected to be approved by the 
Korean Food and Drug Administration for marketing in Korea. Further studies investigating 
the efficacy of the new biologics and related clinical characteristics in severe eosinophilic 
asthma should be conducted in the near future.
A comparison of GINA step 4 and 5 treatment groups to determine the difference in 
characteristics according to severity showed that allergen sensitization rates, family history of 
allergic diseases and lung functions were lower in patients with higher severity. In contrast, 
hypertension was more common in the GINA step 5 treatment group. This is consistent with 
lower lung functions in patients with severe asthma in the SARP study,17 which also showed a 
decrease in the proportion of atopy in severe patients. However, direct comparison is limited 
because in the SARP study, lung function results varied among clusters classified by atopy 
status.17 Among them, cluster 3 (late-onset nonatopic asthma) and 5 (severe asthma with 
fixed airflow) showed low rates of atopy. In addition, there was a higher rate of hypertension 
in the cluster 3 and 5 groups.17 Similar to our study, the U-BIOPRED study also showed lower 
pulmonary functions and lower rates of atopy in patients with severe asthma compared to 
those with mild to moderate asthma.18 Hypertension was not recorded in the U-BIOPRED 
study and could not be compared.18
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Regarding sputum inflammatory cells, the proportion of macrophages was higher and 
neutrophils and lymphocytes were lower in the step 5 treatment group than in the step 4 
treatment group, and there was no difference in the proportion of eosinophils. Unlike our 
study, the proportions of sputum eosinophils and neutrophils were higher in patients with 
severe asthma in both the SARP and U-BIOPRED studies. Further research is needed to 
elucidate the reasons of this difference.
The rate of ICS + LABA combination prescription was lower in the step 5 group than in the 
step 4 group, paradoxically, presumably because the patients in the step 5 group were treated 
with other drugs, such as anti-IgE antibody and systemic corticosteroids. Furthermore, there 
were more unexpected outpatient visits and corticosteroids burst treatment in patients in the 
step 5 treatment group, which may also reflect the severity of their condition.
There are several limitations to this study. This study is an analysis of a severe asthmatic 
patient cohort alone; thus, it is difficult to identify the clinical characteristics of severe 
asthmatics compared to those of non-severe asthmatic patients. In order to overcome this 
limitation, comparative analysis with other general asthma cohorts should be performed. 
In addition, because we used survey questionnaires, the patients' responses could be 
inaccurate. Despite these limitations, this real-world study is meaningful to understand the 
current situation and clinical features of Korean severe asthmatic patients.
In conclusion, severe asthmatic patients in Korea had poor asthma control, high frequency 
of exacerbations, and considerable use of healthcare facilities and asthma medications. This 
study confirmed the burden of severe asthma through these objective data. This study is also 
expected to contain useful, basic data for finding and applying future treatments for severe 
asthma. The severe asthma cohort will be of great help in the understanding of the disease 
and the affected patients, with more expanded data and analysis in the future.
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